|
Market Closed -
Nasdaq
23:00:00 11/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 220.75 USD | +4.56% |
|
+6.81% | +20.87% |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 11,563 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | 25.58% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 11,407 | 11,128 | 10,664 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | 25.73% | -2.44% | -4.17% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -82.5x | 47.9x | 17.3x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 146x | 38.6x | 14.3x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 3x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 12x | 7.4x | 5.16x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 11.8x | 7.12x | 4.76x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -84.8x | 52.1x | 22.4x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -84.4x | 38.8x | 13x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -72.8x | 28.5x | 14.7x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -1.37% | 3.51% | 6.82% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -2.675 | 4.606 | 12.76 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 966.2 | 1,562 | 2,239 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -134.5 | 213.6 | 475.3 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -135.1 | 286.5 | 823.1 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -140.3 | 255.3 | 721 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -156.5 | -435.3 | -898.9 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 220.75 | 220.75 | 220.75 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 52,381 | - | - |
| Announcement Date | 3/1/22 A | 2/27/23 A | 2/20/24 A | 2/18/25 A | 2/23/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -82.53x | 11.81x | -84.78x | -.--% | 11.56B | |
| 18.1x | 4.19x | 9.84x | 0.5% | 78.04B | |
| -17.17x | 25.62x | -16.63x | -.--% | 57.48B | |
| 19.65x | 4.21x | 13.08x | 2.5% | 57.4B | |
| 34.47x | 11.73x | 22.49x | -.--% | 48.81B | |
| 20.54x | 4.54x | 12.95x | 0.71% | 45.5B | |
| 37.49x | 3.54x | 13.51x | -.--% | 32.08B | |
| 54.21x | 3.43x | 26.59x | -.--% | 24.62B | |
| 62.21x | 6.52x | 39.5x | -.--% | 20.77B | |
| 22.98x | 4.94x | 12.86x | -.--% | 15.75B | |
| Average | 16.99x | 8.05x | 4.94x | 0.37% | 39.2B | |
| Weighted average by Cap. | 18.89x | 8.59x | 8.62x | 0.55% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
